Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Onboarding of siponimod in secondary progressive multiple sclerosis patients in Australia: Novel, real-world evidence from the MSGo digital support programme.
Hardy TA, Aouad P, Barnett MH, Blum S, Broadley S, Carroll WM, Crimmins D, Griffiths D, Hodgkinson S, Lechner-Scott J, Lee A, Malhotra R, McCombe P, Parratt J, Plummer C, Van der Walt A, Martel K, Walker RA. Hardy TA, et al. Among authors: broadley s. Mult Scler J Exp Transl Clin. 2024 Jan 12;10(1):20552173231226106. doi: 10.1177/20552173231226106. eCollection 2024 Jan-Mar. Mult Scler J Exp Transl Clin. 2024. PMID: 38222025 Free PMC article.
Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis.
Lee SH, Harold D, Nyholt DR; ANZGene Consortium; International Endogene Consortium; Genetic and Environmental Risk for Alzheimer's disease Consortium; Goddard ME, Zondervan KT, Williams J, Montgomery GW, Wray NR, Visscher PM. Lee SH, et al. Hum Mol Genet. 2013 Feb 15;22(4):832-41. doi: 10.1093/hmg/dds491. Epub 2012 Nov 28. Hum Mol Genet. 2013. PMID: 23193196 Free PMC article.
Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season.
Parnell GP, Gatt PN, McKay FC, Schibeci S, Krupa M, Powell JE, Visscher PM, Montgomery GW, Lechner-Scott J, Broadley S, Liddle C, Slee M, Vucic S, Stewart GJ, Booth DR. Parnell GP, et al. Among authors: broadley s. Mult Scler. 2014 May;20(6):675-85. doi: 10.1177/1352458513507819. Epub 2013 Oct 14. Mult Scler. 2014. PMID: 24126065
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.
Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium; Wiley JS. Gu BJ, et al. Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17. Hum Mol Genet. 2015. PMID: 26188005
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, Fung VSC, White OB, Broadley S, Lechner-Scott J, Vucic S, Henderson APD, Barnett MH, Reddel SW, Brilot F, Dale RC; Australasian and New Zealand MOG Study Group. Ramanathan S, et al. Among authors: broadley s. J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137. doi: 10.1136/jnnp-2017-316880. Epub 2017 Nov 15. J Neurol Neurosurg Psychiatry. 2018. PMID: 29142145 Free PMC article.
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.
Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, Pilli D, Patrick E, van der Walt A, Monif M, Tantsis EM, Yiu EM, Vucic S, Henderson APD, Fok A, Fraser CL, Lechner-Scott J, Reddel SW, Broadley S, Barnett MH, Brown DA, Lunemann JD, Dale RC, Brilot F; Australasian and New Zealand MOG Study Group. Tea F, et al. Among authors: broadley s. Acta Neuropathol Commun. 2019 Sep 3;7(1):145. doi: 10.1186/s40478-019-0786-3. Acta Neuropathol Commun. 2019. PMID: 31481127 Free PMC article.
The effect of emerging nutraceutical interventions for clinical and biological outcomes in multiple sclerosis: A systematic review.
Marx W, Hockey M, McGuinness AJ, Lane M, Christodoulou J, van der Mei I, Berk M, Dean OM, Taylor B, Broadley S, Lechner-Scott J, Jacka FN, Lucas RM, Ponsonby AL; RELIEF Trial team. Marx W, et al. Among authors: broadley s. Mult Scler Relat Disord. 2020 Jan;37:101486. doi: 10.1016/j.msard.2019.101486. Epub 2019 Nov 2. Mult Scler Relat Disord. 2020. PMID: 31707234
173 results